Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Alpha4-integrin antagonism--an effective approach for the treatment of inflammatory diseases?
[Epidemiology of multiple sclerosis in the Primosky Krai and Far East regions.]
In vitro modeling of central nervous system myelination and remyelination.
3D models of human ERα and ERβ complexed with coumestrol.
Memory rehabilitation for people with multiple sclerosis.
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)
Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients.
Physiopathology of symptoms and signs in multiple sclerosis.
Moving towards the pan-European unification of Multiple Sclerosis Nurses: a consensus paper.
Involvement of oxidative stress on the impairment of energy metabolism induced by A beta peptides on PC12 cells: protection by antioxidants.
Two Years Follow up of Domain Specific Cognitive Training in Relapsing Remitting Multiple Sclerosis: A Randomized Clinical Trial.
Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
Extracranial Venous abnormalities: A true pathological finding in patients with multiple sclerosis or an anatomical variant?
Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.
Managing fatigue in patients with multiple sclerosis.
Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
A Herpes Simplex Virus-Derived Replicative Vector Expressing LIF Limits Experimental Demyelinating Disease and Modulates Autoimmunity.
Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: a Phase 1 study.
Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis.
Parent-of-origin effect in multiple sclerosis: observations in half-siblings.
Immunology 2012
Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4).
A case of natalizumab-associated progressive multifocal leukoencephalopathy with repeated negative CSF JC virus testing.
Cytotoxic NKG2C+ CD4 T Cells Target Oligodendrocytes in Multiple Sclerosis.
Platelets Contribute to the Pathogenesis of Experimental Autoimmune Encephalomyelitis.
Pages
« first
‹ previous
…
145
146
147
148
149
150
151
152
153
…
next ›
last »